Evidence map›Paper›PMID 41298591›Full record

ArticleScientific reports2025

Inflammatory response in bacteremia survivors and non-survivors: a case-control study.

Markus Jt Ojanen, Tapio Seiskari, Janne Aittoniemi, Heini Huhtala, Reetta Huttunen, Jaana Syrjänen, Ilkka Junttila, Marko Pesu, Juha Rannikko

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Markus Jt OjanenFaculty of Medicine and Health Technology, Tampere University, Tampere, Box 100, FI- 33014, Finland.
Tapio SeiskariDepartment of Clinical Microbiology, Fimlab Laboratories, Arvo Ylpön katu 4, Tampere, FI- 33520, Finland.
Janne AittoniemiDepartment of Clinical Microbiology, Fimlab Laboratories, Arvo Ylpön katu 4, Tampere, FI- 33520, Finland.
Heini HuhtalaFaculty of Social Sciences, Tampere University, Arvo Ylpön katu 34, Tampere, FI-33520, Finland.
Reetta HuttunenFaculty of Medicine and Health Technology, Tampere University, Tampere, Box 100, FI- 33014, Finland.
Jaana SyrjänenFaculty of Medicine and Health Technology, Tampere University, Tampere, Box 100, FI- 33014, Finland.
Ilkka JunttilaFaculty of Medicine and Health Technology, Tampere University, Tampere, Box 100, FI- 33014, Finland.
Marko PesuFaculty of Medicine and Health Technology, Tampere University, Tampere, Box 100, FI- 33014, Finland.
Juha RannikkoFaculty of Medicine and Health Technology, Tampere University, Tampere, Box 100, FI- 33014, Finland. juha.rannikko@gmail.com.ORCID 0000-0002-7199-6306

Funding

Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital / Fimlab Laboratories / NordLab 9N075Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital / Fimlab Laboratories / NordLab X50060Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital / Fimlab Laboratories / NordLab X50070Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital / Fimlab Laboratories / NordLab X51409
6 · The paper itself

Abstract

Survival in bacteremia is influenced by host comorbidities, pathogen virulence, immune response, and the quality of medical care. A deeper understanding of host inflammatory responses may help identify new biomarkers and therapeutic targets to improve outcomes. In this study, we analyzed plasma samples from adult patients with bacteremia who presented to the emergency department. Patients who died within seven days (n = 44) were compared to matched survivors (n = 44) who lived at least 90 days, with matching based on age, sex, and causative bacterium. Relative concentrations of 92 inflammation-related plasma proteins were measured using the proximity extension assay (Olink Proteomics AB). Of these, 82 proteins were successfully quantified. Thirty proteins, including IL-20RA, CD40, and HGF, were significantly elevated in non-survivors, while three proteins-IFNG, Flt3L, and TNFB-were significantly reduced. Pathway enrichment analysis revealed activation of multiple proinflammatory signaling cascades in non-survivors, particularly those involving IL-6, IL-23, and IL-17. Logistic regression identified HGF, IL-17 C, and Flt3L as key discriminative proteins between groups. These findings indicate that the host inflammatory profile in bacteremia differs markedly between survivors and early non-survivors. Our results highlight potential diagnostic biomarkers for identifying high-risk patients and point to promising therapeutic targets in the management of bacteremia.

Indexed as

BacteremiaInflammationSurvivorsAdultAgedBiomarkersCase-Control StudiesFemaleHumansMaleMiddle AgedProteomicsBiomarkersBacteremiaBiomarkerCytokineSepsis

Identifiers

PMID41298591
PMCPMC12657952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.